Blog
RSS FeedPosted by Michael Wonder on 30 Oct 2023
Celltrion USA announces distribution and incorporation of Yuflyma (adalimumab-aaty), a Humira biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs
26 October 2023 - The treatment will be available on CarePartners Specialty Pharmacy Program in late October and will make ...
Posted by Michael Wonder on 30 Oct 2023
Reforming pharmacy benefit managers - a review of bipartisan legislation
28 October 2023 - Policy makers are considering legislation that would address several well known problems with the pharmacy benefit management ...
Posted by Michael Wonder on 24 Oct 2023
EMA takes further steps to address critical shortages of medicines in the EU
24 October 2023 - Today, the EMA published details of the newly created solidarity mechanism developed by the EMA Medicines Shortages ...
Posted by Michael Wonder on 09 Oct 2023
Who profits most from America’s baffling health care system?
8 October 2023 - Hint: it isn’t big pharma. ...
Posted by Michael Wonder on 07 Oct 2023
Cancer drug shortage eases slightly, but it’s still ‘living from paycheck to paycheck’
5 October 2023 - The shortage of cancer drugs is not going away, but it may be easing slightly, a ...
Posted by Michael Wonder on 24 Sep 2023
New rules for weight loss ‘wonder drug’ after regulator clamp down
23 September 2023 - Australia’s pharmaceuticals regulator has ushered in new rules for a diabetes drug, which is being hailed by ...
Posted by Michael Wonder on 21 Sep 2023
Supply and insurance issues snarl fall COVID-19 vaccine campaign for some
20 September 2023 - It has been just over a week since the US FDA and the US Centers for ...
Posted by Michael Wonder on 18 Sep 2023
COVID-19 vaccine contract summary
18 September 2023 - The Ministry of Health has released a summary of the New Zealand Government’s procurement process for ...
Posted by Michael Wonder on 13 Sep 2023
Treatment options for people with glioma, a type of brain cancer
13 September 2023 - BMS, the supplier of lomustine, a treatment used for a type of brain cancer called glioma, is ...
Posted by Michael Wonder on 07 Sep 2023
Ozempic and Wegovy maker ‘just scratching the surface’ in meeting demand for weight loss drugs, CEO says
5 September 2023 - It could take years before Novo Nordisk has fulfilled demand for its highly popular weight loss ...
Posted by Michael Wonder on 01 Sep 2023
Pharmacy Guild suspends campaign as 60 day dispensing begins
1 September 2023 - The Pharmacy Guild of Australia has agreed to suspend its campaign against 60 day dispensing after ...
Posted by Michael Wonder on 29 Aug 2023
PHARMAC taking action to ensure supply of type 2 diabetes medicine amid worldwide shortage
29 August 2023 - PHARMAC is taking steps to ensure people with type 2 diabetes who take dulaglutide (branded as Trulicity) ...
Posted by Michael Wonder on 24 Aug 2023
Cancer treatment uncertainty: European nations struggle with drug shortages
21 August 2023 - Experts in Europe detail the challenge with current cancer drug shortages and how regulators are trying ...
Posted by Michael Wonder on 16 Aug 2023
The collateral damage of ADHD drug shortages
15 August 2023 - As a new school year begins, parents and doctors find medication shortages are leading to declines in ...
Posted by Michael Wonder on 15 Aug 2023
PHARMAC indicates interest to fund more oestradiol treatments to relieve supply issue
15 August 2023 - PHARMAC is planning to issue a competitive process for supply of oestradiol transdermal products in New Zealand. ...